Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study

OBJECTIVE: Despite the guideline-directed therapy, complete absence of nausea was noted only in 33% of breast cancer patients on anthracycline-cyclophosphamide regimen. Hence, we sought to compare the efficacy of aprepitant (APT) versus olanzapine (OLP) in preventing chemotherapy-induced nausea and...

Descripción completa

Detalles Bibliográficos
Autores principales: Shivaprakash, G., Udupa, Karthik S., Sarayu, V., Thomas, Joseph, Gupta, Vishal, Pallavi, L. C., Pemminati, Sudhakar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892027/
https://www.ncbi.nlm.nih.gov/pubmed/29674800
http://dx.doi.org/10.4103/ijp.IJP_846_16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892027/
https://www.ncbi.nlm.nih.gov/pubmed/29674800
http://dx.doi.org/10.4103/ijp.IJP_846_16

Ejemplares similares